XML 72 R48.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Shareholders' Equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 10 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 22, 2024 | Jan. 07, 2024 | Aug. 09, 2024 | May 31, 2024 | Jun. 30, 2024 | Mar. 31, 2024 | Jun. 30, 2024 | Jun. 30, 2024 | Jun. 30, 2024 | Aug. 09, 2024 | May 01, 2024 | Oct. 31, 2023
Purchase Agreement, Knopp Amendment |  |  |  |  |  |  |  |  |  |  |  |
Nature of business [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued (shares) |  |  |  | 1,872,874 |  |  |  |  |  |  |  |
Issuance of common shares, net of offering costs |  |  |  | $ 65,981 |  |  |  |  |  |  |  |
Pyramid Biosciences, Inc. |  |  |  |  |  |  |  |  |  |  |  |
Nature of business [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment of common shares, shares (in shares) |  | 255,794,000 |  |  |  |  |  |  |  |  |  |
Upfront payment of common shares, value |  | $ 10,894 |  |  |  |  |  |  |  |  |  |
Upfront payment of common shares, shares issued (in shares) |  |  |  |  |  |  | 253,410,000 |  |  |  |  |
Research and development |  |  |  |  |  | $ 5,689 |  |  |  |  |  |
Common shares issuable (in shares) |  |  |  |  |  | 98,129 |  |  |  |  |  |
Common shares issued (in shares) |  |  |  |  |  |  |  | 97,233 |  |  |  |
Common Shares |  |  |  |  |  |  |  |  |  |  |  |
Nature of business [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued (shares) |  |  |  |  | 8,544,951 |  |  |  |  |  |  |
Issuance of common shares, net of offering costs |  |  |  |  | $ 317,720 |  |  |  |  |  |  |
Number of shares sold in transaction (in shares) | 6,451,220 |  |  |  |  |  |  |  |  |  |  |
Issuance price per share (in dollars per share) | $ 41.00 |  |  |  |  |  |  |  |  |  |  |
Proceeds from sale of stock | $ 247,830 |  |  |  |  |  |  |  |  |  |  |
Equity Distribution Agreement aggregate amount |  |  |  |  |  |  |  |  |  |  |  | $ 150,000
Purchase Agreement, Knopp Amendment |  |  |  |  |  |  |  |  |  |  |  |
Nature of business [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Number of securities called by warrants (shares) |  |  |  |  |  |  |  |  |  |  | 294,195 |
Exercise price of warrants (in dollars per share) |  |  |  |  |  |  |  |  |  |  | $ 67.98 |
Warrants, fair value disclosure |  |  |  |  |  |  |  |  |  |  | $ 3,340 |
Equity Distribution Agreement | Common Shares |  |  |  |  |  |  |  |  |  |  |  |
Nature of business [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued (shares) |  |  |  |  |  |  |  |  | 2,093,731 |  |  |
Proceeds from sale of stock |  |  |  |  |  |  |  |  | $ 69,890 |  |  |
Equity Distribution Agreement | Common Shares | Subsequent event |  |  |  |  |  |  |  |  |  |  |  |
Nature of business [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued (shares) |  |  | 2,154,857 |  |  |  |  |  |  | 4,248,588 |  |
Proceeds from sale of stock |  |  | $ 76,360 |  |  |  |  |  |  | $ 146,250 |  |

X
- Definition Acquisition, Consideration Transferred, Equity Interest Issued and Issuable + References No definition available. + Details
Name: | bhvn_AcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
Namespace Prefix: | bhvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Acquisition, Consideration Transferred, Equity Interest Issued and Issuable, Shares + References No definition available. + Details
Name: | bhvn_AcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
Namespace Prefix: | bhvn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Acquisition, Consideration Transferred, Equity Interest Issued, Shares + References No definition available. + Details
Name: | bhvn_AcquisitionConsiderationTransferredEquityInterestIssuedShares
Namespace Prefix: | bhvn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Developmental Milestone, Equity Interest Issuable, Shares + References No definition available. + Details
Name: | bhvn_DevelopmentalMilestoneEquityInterestIssuableShares
Namespace Prefix: | bhvn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Developmental Milestone, Equity Interest Issued, Shares + References No definition available. + Details
Name: | bhvn_DevelopmentalMilestoneEquityInterestIssuedShares
Namespace Prefix: | bhvn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Distribution Agreement, Maximum Aggregate Available, Amount + References No definition available. + Details
Name: | bhvn_EquityDistributionAgreementMaximumAggregateAvailableAmount
Namespace Prefix: | bhvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Warrants, Fair Value Disclosure + References No definition available. + Details
Name: | bhvn_WarrantsFairValueDisclosure
Namespace Prefix: | bhvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SubsidiarySaleOfStockLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bhvn_PurchaseAgreementKnoppAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bhvn_AcquisitionAxis=bhvn_PyramidBiosciencesInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=bhvn_PurchaseAgreementKnoppAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=bhvn_EquityDistributionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |